-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
US travel woes mount as govt shutdown prompts flight cuts
-
North Korea fires unidentified ballistic missile: Seoul military
-
West Bank's ancient olive tree a 'symbol of Palestinian endurance'
-
Global tech tensions overshadow Web Summit's AI and robots
-
Green shines as Suns thump Clippers 115-102
-
Japan to screen #MeToo film months after Oscar nomination
-
Erasmus relishing 'brutal' France re-match on Paris return
-
Rejuvenated Vlahovic taking the reins for Juve ahead of Turin derby
-
'Well-oiled' Leipzig humming along in Bayern's slipstream
-
Bangladesh cricket probes sexual harassment claims
-
NFL-best Broncos edge Raiders to win seventh in a row
-
Deadly Typhoon Kalmaegi ravages Vietnam, Philippines
-
Three killed in new US strike on alleged drug boat, toll at 70
-
Chinese microdrama creators turn to AI despite job loss concerns
-
Trump hails Central Asia's 'unbelievable potential' at summit
-
Kolya, the Ukrainian teen preparing for frontline battle
-
Big leap in quest to get to bottom of climate ice mystery
-
Markets drop as valuations and US jobs, rates spook investors
-
'Soap opera on cocaine': how vertical dramas flipped Hollywood
-
Under pressure? EU states on edge over migrant burden-sharing
-
US influencers falsely associate Mamdani with extremist group
-
Hungary's Orban to meet Trump in face of Russia oil sanctions
-
US facing travel chaos as flights cut due to govt shutdown
-
Liverpool and Man City renew rivalry as they try to narrow Arsenal gap
-
UK's Andrew asked to testify over Epstein as he formally loses titles
-
Local hero: 'DC sandwich guy' found not guilty of assaulting officer with sub
-
Dead famous: Paris puts heritage graves up for grabs
-
UK grandmother on Indonesia death row flies home
-
Former NFL star Brown extradited from Dubai to face trial in shooting - police
-
How to Sell Your Small Business Fast (Guide Release)
-
Chile presidential hopeful vows to expel 'criminal' migrants to El Salvador
-
Trump event paused in Oval Office when guest faints
-
NFL Colts add Sauce to recipe while Patriots confront Baker
-
Home owned by Miami Heat coach Spoelstra damaged by fire
-
Tesla shareholders approve Musk's $1 trillion pay package
-
World leaders launch fund to save forests, get first $5 bn
-
Villa edge Maccabi Tel Aviv in fraught Europa League match
-
Protests as Villa beat Maccabi Tel Aviv under tight security
-
US Supreme Court backs Trump admin's passport gender policy
-
Japan boss Jones backs Farrell to revive Ireland's fortunes
-
MLB Padres name former reliever Stammen new manager
-
'Grand Theft Auto VI' video game delayed again until Nov. 2026
-
Martino returns as head coach of MLS Atlanta United
-
Hamilton dismisses Ferrari exit claims
-
Musetti keeps ATP Finals hopes alive, joins Djokovic in Athens semis
-
England boss Borthwick wants 'brilliant' Marcus Smith to shine against Fiji
-
Piastri says he is confident he can recover and win drivers' title
-
Verstappen admits he may need a bit of 'luck' to haul in rivals in title race
-
Kazakhstan to join Abraham Accords as Trump pushes Mideast peace
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Norris--AMWN